Medicine & Health

Hypothesis

Serial measurement of serum growth differentiation factor-15 (GDF-15), an integrated stress response marker reflecting mitochondrial dysfunction, combined with a non-invasive skeletal muscle mitochondrial complex IV activity index derived from near-infrared spectroscopy (NIRS) oxygen extraction kinetics during standardized isometric contraction, predicts subclinical cardiac involvement in inflammatory myopathies (dermatomyositis, polymyositis, anti-synthetase syndrome) 8–20 weeks before conventional cardiac biomarker (troponin I/T, NT-proBNP) elevation.

Rationale

Inflammatory myopathies carry underappreciated cardiac risk: subclinical myocarditis occurs in 30–75% of patients at autopsy, yet clinical detection relies on late markers (troponin elevation, echocardiographic dysfunction). GDF-15 rises in response to mitochondrial stress across multiple tissues, including cardiomyocytes, and is elevated in heart failure, myocarditis, and mitochondrial myopathies. Skeletal muscle mitochondrial dysfunction — measurable non-invasively via NIRS-derived oxygen extraction recovery kinetics — may serve as a sentinel for systemic mitochondrial impairment affecting the myocardium.

The key insight: inflammatory myopathies produce a systemic mitochondrial insult (via interferon-driven disruption of oxidative phosphorylation complexes, particularly complex IV/cytochrome c oxidase). Skeletal muscle is more accessible to non-invasive functional assessment than myocardium, and mitochondrial dysfunction in skeletal muscle may precede — or at minimum parallel — cardiac mitoch

Background: Central nervous system involvement in primary Sjögren syndrome (pSS) affects 2–5% of patients and carries significant morbidity, yet diagnosis relies on MRI findings that appear late in the pathological cascade. CSF cell-free mitochondrial DNA (cf-mtDNA) is released during neuronal and endothelial mitochondrial stress, while intrathecal type I interferon production is a hallmark of pSS pathogenesis. We hypothesize that the combination of these two biomarkers captures the pre-imaging neurovascular inflammatory window.

Hypothesis: In patients with established pSS, serial CSF cf-mtDNA copy number (quantified by droplet digital PCR targeting MT-ND1 and MT-ND4) combined with intrathecal IFN-α index (CSF IFN-α / serum IFN-α × albumin quotient) will predict MRI-confirmed CNS vasculitis 8–20 weeks before lesion appearance with >80% sensitivity and >75% specificity. The cf-mtDNA/IFN-α composite score will outperform each biomarker alone (AUROC improvement ≥0.10) and conventional CSF markers (oligoclonal bands, IgG index, cell count).

Mechanistic rationale: Type I IFN signaling in pSS drives endothelial activation and blood-brain barrier dysfunction via JAK-STAT-mediated upregulation of CXCL10 and VCAM-1 on cerebral microvasculature. This permits perivascular lymphocytic infiltration (predominantly CD4+ T cells and B cells), which induces mitochondrial stress in endothelial cells and adjacent neurons via TNF-α and complement C5a-mediated mitochondrial permeability transition pore opening. The resultant release of cf-mtDNA into CSF acts as a DAMP, amplifying

This hypothesis suggests that the onset of cancer is not primarily driven by mutations, but by the physical failure of liquid-liquid phase separation within the chromatin of the nucleus. Imagine the nucleus not just as a mix of DNA and proteins, but as a complex ecosystem of distinct, immiscible liquid droplets, similar to oil in water. Healthy cells maintain tightly controlled compartments (called condensates) where silencing proteins are concentrated to keep specific genes off, and other compartments where transcription machinery is concentrated to keep necessary genes on.

According to this hypothesis, cancer arises when the physical properties (like viscosity or surface tension) of these chromatin condensates break down—a "phase separation collapse." A triggering event (which could be epigenetic changes, environmental stress, or metabolic shifts) alters the concentration or structure of key proteins (like certain methyltransferases or readers) that drive phase separation.

IF a dual-regulatory allotopic ND1 construct — encoding nuclear-codon-recoded ND1 (CAI ≈ 0.70) fused to the Su9-DHFR mitochondrial targeting sequence (MTS), placed under a ROS-responsive ARE/NRF2-driven minimal promoter (rather than constitutive CMV) with an attenuated Kozak sequence, delivered by lentiviral transduction (MOI = 5, single administration)

is stably integrated into aged (24-month-old) C57BL/6J mice via subretinal AAV9 co-delivery (for retinal ganglion cell [RGC] targeting) and systemically by intravitreal injection, in animals harboring accumulated somatic mtDNA mutations in RGC-enriched retinal tissue (confirmed by long-range PCR heteroplasmy quantification),

THEN at 12 weeks post-injection: (i) RGC-layer Complex I–linked oxygen consumption rate (Seahorse XF, rotenone-sensitive fraction, ex vivo retinal explants) will recover ≥60% relative to aged vehicle-injected controls; (ii) precursor ND1 protein import rate (pulse-chase ³⁵S-Met/Cys, 30-min chase, immunoprecipitation of mature vs. precursor band) will exceed that of a matched CAI ≈ 0.95 construct by ≥1.5-fold in age-matched cybrid lines; (iii) cytosolic ND1 precursor aggregation (filter trap assay, anti-ND1, cytosolic fraction) will be ≤20% of total ND1 signal — versus ≥50% aggregate fraction predicted for the CAI ≈ 0.95 control in aged cells where TIM23 capacity is further diminished,

BECAUSE:

1. Maximally codon-optimized (CAI ≈ 0.95) constructs drive burst-rate ribosomal translation that generates precursor protein flux exceeding TIM23 translocase stoichiometric throughput, causing cytosoli

Background

Dermatomyositis (DM) carries a 15–30% risk of occult malignancy, typically manifesting within 3 years of diagnosis. Current screening relies on age-appropriate cancer protocols (CT, colonoscopy, tumor markers), which detect malignancies only after significant tumor burden accumulates. Meanwhile, cell-free DNA (cfDNA) fragmentomics — the analysis of DNA fragment length distributions, end-motif preferences, and nucleosome positioning patterns — has demonstrated remarkable sensitivity for early cancer detection in non-autoimmune populations (Cristiano et al., Nature 2019; Jiang et al., Cancer Discovery 2020).

Hypothesis

We hypothesize that cfDNA fragmentomic end-motif signatures (4-mer terminal nucleotide frequencies) differ systematically between cancer-associated dermatomyositis (CADM-malignancy) and idiopathic dermatomyositis at the time of myositis diagnosis, enabling discrimination of occult malignancy 6–14 months before conventional screening detection, with an AUROC >0.85.

Mechanistic Rationale

In cancer-associated DM, tumor-derived cfDNA undergoes distinct nuclease processing compared to muscle-derived inflammatory cfDNA. Tumor apoptosis preferentially generates fragments with CC/CG-enriched end-motifs via caspase-activated DNase (CAD) and DNASE1L3, while muscle necrosis in DM produces fragments with T-rich end-motifs characteristic of DNASE1-mediated degradation. This differential nuclease activity creates a detectable "fragmentomic fingerprint" even when tumor-derived cfDNA constitutes <1% of total cfDNA.

Additionally, nucleosome positio

IF a panel of conformation-selective single-chain antibody fragments (scFvs), generated via AI epitope-guided phage display with obligate negative-selection counter-panning against full-length recombinant MFGE8, is administered by intraperitoneal injection (10 mg/kg, twice weekly for 12 weeks) to aged male and female C57BL/6J mice (≥20 months of age, an age at which aortic medin amyloid is well-established),

THEN quantitative immunohistochemistry will show ≥40% reduction in aortic medial medin amyloid burden, accompanied by ≥10% reduction in carotid-to-abdominal aortic pulse wave velocity (PWV) measured by high-frequency pulsed-wave Doppler ultrasound (VisualSonics Vevo platform), compared to isotype-control-treated aged mice,

BECAUSE the following causal chain operates:

1. Medin, a 50-amino acid intrinsically disordered peptide derived from proteolytic cleavage of the C2 domain of MFGE8/lactadherin, accumulates in the aortic media during aging, forming beta-sheet-rich amyloid fibrils that embed between smooth muscle cells and elastic laminae, mechanically stiffening the vessel wall (Häggqvist et al. 1999, and Degenhardt et al. 2020, as described in the Evidence Set). In fibrillar conformation, previously buried aggregation-prone regions (APRs) — predicted computationally to reside in the C-terminal half of the medin sequence (approximately residues 30–50) — are exposed as neo-epitopes absent from the parent MFGE8 protein.

2. AI-based structural prediction tools (e.g., AlphaFold2 combined with aggregation prediction algorithms such as TANGO or Zyggregator) can map these

This hypothesis explores an underappreciated dimension of cellular aging.

Hypothesis

Entropic regularization of optimal transport (Sinkhorn divergence) applied to patient pharmacogenomic feature distributions — encoding CYP2C19, CYP3A4, NAT2, HLA-DRB1, and ABCB1 haplotype embeddings alongside serial DAS28 trajectories — enables distributional treatment matching that identifies biologic-to-patient pairings minimizing expected disease burden, reducing median time-to-DAS28 remission by >25% compared to guideline-based sequential switching.

Background and Rationale

Current treat-to-target strategies in rheumatoid arthritis (RA) rely on sequential biologic switching guided by composite disease activity indices, with pharmacogenomic data — when used at all — informing binary go/no-go decisions (e.g., HLA-B*5801 for allopurinol). This ignores the rich distributional structure of patient populations across high-dimensional pharmacogenomic spaces. Optimal transport (OT) theory provides a principled framework for comparing and mapping probability distributions, with Sinkhorn divergence offering computationally tractable entropic regularization that scales to large cohorts.

By representing each treatment arm as an empirical distribution over pharmacogenomic-clinical outcome pairs and each incoming patient as a point (or uncertain distribution) in the same feature space, the Sinkhorn barycentric projection identifies the treatment distribution to which the patient is closest in Wasserstein sense, accounting for the full geometry of the feature space rather than marginal biomarker thresholds.

Testable Predictions

1. Primary: In a retrospect

Background

Biologic selection in SLE remains empirical. Belimumab (anti-BAFF) and rituximab (anti-CD20) target distinct B-cell survival and depletion mechanisms, yet no validated biomarker guides the choice between them. B-cell receptor (BCR) somatic hypermutation (SHM) load reflects germinal center activity and affinity maturation intensity — processes differentially dependent on BAFF signaling versus CD20-expressing cell pools.

Hypothesis

Circulating plasmablast BCR heavy-chain SHM load, quantified by targeted next-generation sequencing of VDJ regions at baseline, stratifies SLE patients into BAFF-dependent (high SHM, active germinal centers) versus extrafollicular (low SHM, short-lived plasmablasts) pathogenic B-cell programs. High SHM load (>8 mutations/VH region) predicts superior response to belimumab (BAFF blockade disrupts germinal center output), while low SHM load (<4 mutations/VH) predicts superior response to rituximab (direct depletion of extrafollicular short-lived effectors).

Testable Predictions

1. Baseline plasmablast SHM load >8 mutations/VH predicts SRI-4 response to belimumab at week 12 with AUC >0.80
2. Baseline SHM load <4 mutations/VH predicts complete B-cell depletion and SLEDAI improvement ≥4 points with rituximab at week 12 with AUC >0.78
3. Intermediate SHM (4–8 mutations/VH) identifies mixed pathogenesis where combination or sequential therapy outperforms monobiologic
4. SHM load correlates with serum BAFF levels (r >0.5) and inversely with anti-dsDNA avidity index

Proposed Methodology

Background

TNF-related apoptosis-inducing ligand (TRAIL) plays a dual role in immune homeostasis: it eliminates autoreactive lymphocytes via apoptosis and modulates dendritic cell activation thresholds. In systemic lupus erythematosus (SLE), defective TRAIL-mediated apoptosis of autoreactive B cells has been implicated in disease pathogenesis, yet serum soluble TRAIL (sTRAIL) kinetics remain underexplored as a biomarker for renal flare prediction.

Hypothesis

We hypothesize that the rate of sTRAIL decline over serial measurements (slope ≤ −0.15 ng/mL/week over 4 consecutive biweekly samples), when combined with a concurrent rise in circulating plasmablast frequency (≥2-fold increase from individual baseline by flow cytometry, CD19+CD27hiCD38hi), predicts worsening of the NIH Activity Index on renal biopsy 8–16 weeks before conventional proteinuria thresholds (>0.5 g/24h or UPCR >0.5) are crossed.

The proposed mechanism involves three converging pathways:

1. TRAIL decoy receptor upregulation: Inflamed renal tissue upregulates DcR1/DcR2, sequestering TRAIL locally and reducing circulating sTRAIL. This creates a "TRAIL sink" proportional to intrarenal inflammation.
2. Escape from peripheral tolerance: As sTRAIL falls below the threshold for autoreactive B-cell deletion, surviving clones differentiate into plasmablasts producing nephritogenic autoantibodies (anti-dsDNA, anti-C1q).
3. Temporal lag: Histological activity (mesangial/endocapillary proliferation, crescents) precedes glomerular filtration barrier breakdown, creating a detectable window where bio

What if cellular senescence is a developmental program repurposed by aging? This question probes the mechanisms underlying age-related decline. Understanding this could reveal new intervention points.

Hypothesis: Senescent osteoclasts accumulating in subchondral bone with aging release extracellular vesicles (EVs) enriched in miR-34a and hypomethylated mitochondrial DNA fragments. These EVs are taken up by synovial tissue-resident macrophages, where they inhibit SIRT1-dependent deacetylation of NF-kB p65 and activate cGAS-STING signaling, epigenetically reprogramming macrophages toward a sustained pro-inflammatory (SASP-like) secretome.

This creates a feed-forward loop: senescent osteoclast EVs → macrophage inflammaging → accelerated osteoclastogenesis → more senescent osteoclasts.

Testable prediction: Selective clearance of p16^INK4a-positive osteoclasts using bone-targeted senolytics (dasatinib conjugated to bisphosphonate scaffolds) would reduce synovial macrophage SASP markers (IL-6, MMP-3, CXCL10) by >40% in aged mice with collagen-induced arthritis at 8 weeks post-treatment.

Experimental design: Use p16-3MR transgenic mice with GCV-mediated senescent cell ablation restricted to the osteoclast lineage (LysM-Cre x p16-3MR). Compare synovial fluid cytokine profiles and H3K27ac ChIP-seq on macrophage inflammatory gene promoters between ablated and control groups.

A positive result would establish senescent osteoclasts as an upstream driver of age-related erosive arthritis and validate bone-targeted senolysis as a disease-modifying strategy at the intersection of geroscience and rheumatology.

Is clonal hematopoiesis a window into systemic aging? This question probes the mechanisms underlying age-related decline. Understanding this could reveal new intervention points.

This hypothesis suggests that DNA isn't just a blueprint for proteins, but a biological antenna tuned to a specific, low-frequency cosmic "clock" emitted by the galactic core. According to TRM, human cells are designed to stay in a state of perfect repair as long as they remain in phase with this universal frequency. However, as our solar system moves through different densities of dark matter in its galactic orbit, "gravitational static" begins to interfere with the signal. Aging, therefore, is the biological equivalent of radio static: our cells lose the ability to hear the "maintenance" signal from the cosmos, leading to the chaotic protein folding and cellular senescence we mistake for natural decay. We aren't "wearing out"; we are simply falling out of sync with the rhythm that keeps matter organized.

Background

Tubulointerstitial fibrosis (TIF) is the strongest histological predictor of long-term renal outcome in lupus nephritis (LN), yet current monitoring relies on proteinuria and eGFR — lagging indicators that reflect glomerular damage rather than the fibrotic process itself. By the time eGFR declines, substantial irreversible interstitial injury has already occurred.

Osteopontin (OPN), a matricellular phosphoglycoprotein, exists as multiple splice variants with divergent biological functions. OPN-a (full-length) promotes inflammation and macrophage chemotaxis, while OPN-c (lacking exon 4) drives myofibroblast differentiation and extracellular matrix deposition via integrin αvβ3-mediated TGF-β1 activation. Crucially, the OPN-a/OPN-c ratio in serum has been shown to shift toward OPN-c dominance during active fibrogenesis in hepatic and pulmonary fibrosis models, but has not been systematically evaluated in renal fibrosis.

Concurrently, urinary monocyte chemoattractant protein-1 (MCP-1/CCL2) reflects tubular epithelial activation and macrophage infiltration — the cellular machinery that precedes and drives TIF.

Hypothesis

Serial measurement of the serum OPN-a/OPN-c splice variant ratio, combined with urinary MCP-1 trajectory slope, will identify active tubulointerstitial fibrogenesis in lupus nephritis 8–20 weeks before clinically detectable eGFR decline.

Specifically:

1. A sustained OPN-a/OPN-c ratio decline below 1.5 over 4 consecutive weeks indicates a shift from inflammatory to fibrotic dominance
2. Concurrent urinary MCP-1 slope >15 pg/mg creatinine/we

Can we map the senescence-associated secretory phenotype (SASP) as a network? This question probes the mechanisms underlying age-related decline. Understanding this could reveal new intervention points.